Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 4/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302087 | 1.00 | KLK7 (0.33) | KLK7PPARABCHEACHECHRM2 | |
| SCHEMBL2301403 | 0.92 | PPARA (0.36) | KLK7PPARABCHEACHEKLK5 | |
| SCHEMBL2301398 | 0.92 | PPARA (0.36) | KLK7PPARABCHEACHEKLK5 | |
| SCHEMBL2300128 | 0.92 | PPARA (0.35) | KLK7PPARABCHEACHEKLK5 | |
| SCHEMBL2300125 | 0.92 | PPARA (0.35) | KLK7PPARABCHEACHEKLK5 | |
| SCHEMBL2302447 | 0.92 | PPARA (0.36) | KLK7PPARAKLK5PPARGPTPN1 | |
| SCHEMBL2302440 | 0.92 | PPARA (0.36) | KLK7PPARAKLK5PPARGPTPN1 | |
| SCHEMBL2304511 | 0.87 | LTA4H (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2304516 | 0.87 | LTA4H (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13784389 | 0.82 | HPGD (0.36) | PPARAPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277439-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND y-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | TANAKA KEIGO (JP) | 2012-11-01 | — | — | US | disclosed |
| US-8188119-B2 | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same | EISAI R&D MANAGEMENT CO., LTD (JP) | 2012-05-29 | — | — | US | disclosed |
| EP-2351752-A1 | PYRIDINE DERIVATIVE HAVING SUBSTITUTED HETERO RING AND SUBSTITUTED y-GLUTAMYLAMINO GROUP, AND ANTI-FUNGAL AGENT COMPRISING SAME | Eisai R&D Management Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20100105737-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND gamma-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105737-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND gamma-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | ASNS, ERG28, GLUL | KLK7 4126/4885PPARA 4236/4885BCHE 2738/4885 |
| US-20120277439-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND y-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | ASNS, GLUL, IL4I1 | KLK7 3866/4885PPARA 4133/4885BCHE 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.